A short news article previewing preclinical in vivo research on a PDE5 inhibitor for autosomal dominant polycystic kidney disease, inviting readers to learn about the study's scientific rationale and next-step development plans.
Key Takeaways
- Udenafil reduced kidney cyst burden and lowered blood urea nitrogen versus controls in a preclinical ADPKD model
- Drug showed activity on the renal cGMP signaling pathway linked to its intended mechanism of action
- Udenafil produced a statistically significant reduction in a preclinical measure of cardiac hypertrophy